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The relationship between plasma free 15-
F2t–isoprostane concentration and early
postoperative cardiac depression
following warm heart surgery
David M. Ansley, MD, Zhengyuan Xia, MD, and Baljinder S. Dhaliwal,
MSc, Vancouver, British Columbia, Canada
Low cardiac output syndrome (LCOS) adversely affects6% to 25% of patients following cardiac surgery.1,2Identifying factors associated with the risk of LCOS isintegral to the development of new strategies to address
this clinical problem. 15-F2t–isoprostane is a novel biologically
active marker of lipid peroxidation and a potent vasoconstrictor3
known to induce ventricular dysfunction following experimental
ischemia-reperfusion.4 Description of 15-F2t–isoprostane genera-
tion during cardiac surgery is limited, and the clinical relevance of
its release and metabolism is unknown. We wanted to determine if
a relationship exists between 15-F2t–isoprostane generation and
early myocardial function following warm heart surgery.
Methods
Following ethics board approval and informed consent, 30 patients
scheduled for coronary artery bypass grafting (CABG; n  24) or
combined valve replacement/CABG (n  6) procedures utilizing
normothermic (34°-37°C) cardiopulmonary bypass (CPB) and
warm antegrade intermittent blood/crystalloid (8:1) cardioplegia
were enrolled. Cardiac index (CI) was determined intraoperatively
and the first 6 postoperative hours using a pulmonary artery
catheter in 26 of 30 patients.
Central venous blood was sampled at baseline, at 30 minutes of
global myocardial ischemia, and at 10 (Rep-10), 30 (Rep-30), and
120 minutes after aortic declamping (reperfusion) for measure-
ment of plasma free 15-F2t–isoprostane by enzyme immunoassay
(EIA) using a highly specific rabbit 15-F2t–isoprostane antibody.
The linearity and accuracy of the assay was assessed in triplicate
with EIA buffer spiked with 15-F2t–isoprostane standard over
therange of 3.9 of 250 pg/mL. The best assay linearity relationship
exists between 7.8 to 125 pg/mL (R2  0.9998). The intra-assay
and interassay coefficient of variation was less than 9% or less than
14.7% when plasma free 15-F2t–isoprostane was in the range of 14
to 58 pg/mL.
Student t test was used to compare preanesthesia and during
CPB patient data. Isoprostane data were compared by 2-way
analysis of variance with Bonferroni’s correction (GraphPad
Prism). Correlations were evaluated by the Pearson test and 95%
confidence intervals derived. The differences were considered
significant at P  .05.
Results
The demographic and perioperative data for the 30 patients are
presented in Table 1. No perioperative myocardial ischemia was
detected in any patient.
Overall, the plasma free 15-F2t–isoprostane level increased
significantly during ischemia (210.2 31.0 pg/mL, mean SEM)
compared with baseline (75.9  9.2 pg/mL; P  .001), remained
elevated at Rep-10 (158.1 21.3 pg/mL), and returned to baseline
levels at Rep-30 (117.2  13.6 pg/mL) and onward (P  .05).
There was no relation between plasma 15-F2t–isoprostane and
duration of aortic crossclamping (ACC) or CPB.
Postoperative cardiac index was 2.2 L · min · m2 in 6 of 26
patients in whom the 15-F2t–isoprostane concentration did not
change or increased during 10 to 30 minutes of reperfusion. These
patients required 2 inotropes (n  6) for postoperative hemody-
namic stabilization. In contrast, 15-F2t–isoprostane decreased ex-
ponentially during reperfusion in patients who did not need ino-
tropic support (n  7). There was no significant difference in
duration of ACC and CPB, mean systemic oxygenation during
surgery, hemoglobin content of cardioplegia, volume and fre-
quency of cardioplegia, or systemic oxygen tension during CPB
between these subgroups.
A significant negative correlation was observed between post-
operative CI and percentage change in plasma 15-F2t–isoprostane
concentration from Rep-10 to Rep-30 for 26 patients (Figure 1;
r  0.7278; 95% CI: 0.8699 to 0.4740, P  .0001). Postop-
erative cardiac index did not correlate with baseline 15-F2t–iso-
prostane nor with the 15-F2t–isoprostane concentration during
ischemia (P  .1).
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Discussion
Evidence documenting the clinical relevance of oxidant stress in
cardiac surgery is lacking. 15-F2t–isoprostane formation has been
implicated in PTCA-associated complications such as coronary
vasospasm,5 but investigation of a role in myocardial stunning is
required. The relationship between 15-F2t–isoprostane formation
and postoperative cardiac function, if one exists, is unknown.
The mechanism of cardiac depression seen in our patients has
yet to be determined. Postoperative myocardial ischemia was not
evident. To the best of our knowledge, we provide first evidence
that 15-F2t–isoprostane formation and metabolism may be a factor
in postoperative recovery of cardiac function. We describe an
association between the level of plasma free 15-F2t–isoprostane
and postoperative CI. Although elevated primarily during isch-
emia, the pattern of 15-F2t–isoprostane degradation during reper-
fusion appears clinically relevant. In this series of patients, persis-
tent intraoperative elevation of 15-F2t–isoprostane during
reperfusion was associated with increased need for hemodynamic
stabilization following CABG surgery. This occurs independent of
the timing and hemoglobin content of cardioplegic protection, 2
factors in low cardiac output syndrome. Alterations in its forma-
tion, metabolism, and elimination during surgery may explain
these effects.
Determination of the mechanism(s) will be important in the
development of new therapies that prevent or treat postopera-
tive cardiac depression. A role for 15-F2t–isoprostane in the
pathogenesis of myocardial IRI is suggested. However, this
hypothesis requires further testing with agents designed to
antagonize its effects to confirm if a cause-and-effect relation-
ship indeed exists.
We acknowledge Mr L. G. Franciosi for statistical advice.
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Figure 1. Correlation between postoperative cardiac index (CI)
and changes of plasma free 15-F2t–isoprostane during early
reperfusion. CI was significantly negatively correlated with per-
centage increase of 8-F2–isoprostane from 10 minutes of reper-
fusion (Rep-10) to 30 minutes of reperfusion (Rep-30; r  0.7278,
95% CI: 0.8699 to 0.4740, P < .0001). n  26. CI data not
available in 4 patients.
TABLE 1. Demographic and perioperative data (mean 
SEM)*
Age (y) 67.7 1.6
Sex (male/female) 22/8
Body surface area (m2) 1.97 0.04
NYHA class II-IV
Preoperative LVEF (%) 56.3 2.2
Duration of ACC (min) 100.9 8.5
Duration of CPB (min) 132.1 10.6
Volume of cardioplegia (mL) 5874 785
n  30. ACC, Aortic crossclamping; CPB, cardiopulmonary bypass; LVEF,
left ventricular ejection fraction; NYHA, New York Heart Association
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